Takeda Pharmaceutical Company Limited (NYSE:TAK) Q2 2023 Earnings Conference Call October 26, 2023 6:00 AM ET

Company Participants

Christopher O'Reilly - Head of Investor Relations

Christophe Weber - President and Chief Executive Officer

Andy Plump - President of R&D

Costa Saroukos - Chief Financial Officer

Julie Kim - President, U.S. Business Unit and U.S. Country Head

Ramona Sequeira - President, Global Portfolio Division

Conference Call Participants

Hidemaru Yamaguchi - Citigroup

Shinichiro Muraoka - Morgan Stanley

Seiji Wakao - J.P. Morgan

Steve Barker - Jefferies

Kazuaki Hashiguchi - Daiwa Securities

Michael Nedelcovych - TD Cowen

Miki Sogi - Bernstein

Akinori Ueda - Goldman Sachs

Christopher O'Reilly

Thank you very much for joining us out of your busy schedule today for the earnings call for Second Quarter Fiscal 2023 with Takeda Pharmaceutical Company Limited. I am going to be the moderator today O'Reilly, the Head of IR.

Now let me explain about a language setting. At the bottom of Zoom window, there is language button. If you wish to listen to Japanese, please choose Japanese. And if you wish to listen to English, please choose English. If you just listen to live audio, please turn it off.

Before starting, I'd like to remind everyone that we will be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those discussed today. The factors that could cause our actual results to differ materially are discussed in our most recent Form 20-F and in our other SEC filings. Please also refer to the important notice and page two of the presentation regarding forward-looking statements and our known IFRS financial measures, which will also be discussed during this call. Definitions of our non-IFRS measures and reconciliations with comparable IFRS financial measures are included in appendix to the presentation.

Let's get started with the presentation today. CEO and President, Christophe Weber and President of R&D, Andy Plump; and Chief Financial Officer, Costa Saroukos who will be making presentations each. And then we will open the floor for questions. Let's get started.

Christophe, over to you.

Christophe Weber

Thank you, Chris. Thank you, everyone, for joining us today. It's a real pleasure to be with you all. At Takeda, our vision is to discover and deliver life transforming treatments guided by our commitment to patients, our people, and the planet. This proposed lead approach is at the core of our strategy to deliver long-term value creation for our stakeholders. We are rapidly embracing the use of data, technology, and AI, transforming the company across all functions. We'll provide more details on this remarkable change next year.